Moderna Inc. diskutieren
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at UBS Group AG from $108.00 to $96.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Leerink Partners from $31.00 to $27.00. They now have an "underweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $112.00 to $99.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Bank of America Co. from $41.00 to $34.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at UBS Group AG from $96.00 to $78.00. They now have a "buy" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $40.00 to $33.00. They now have an "underweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $33.00 to $26.00. They now have an "underweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna, Inc. (NASDAQ: MRNA) had its price target lowered by analysts at Bank of America Corporation from $26.00 to $25.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target lowered by analysts at Leerink Partners from $18.00 to $15.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target lowered by analysts at JPMorgan Chase & Co. from $26.00 to $25.00. They now have an "underweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target lowered by analysts at Bank of America Corporation from $24.00 to $21.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its "underperform" rating reaffirmed by analysts at Wolfe Research. They now have a $17.00 price target on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target raised by analysts at Leerink Partners from $15.00 to $18.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) was given a new $63.00 price target on by analysts at Piper Sandler. They now have an "overweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) was upgraded by analysts at BMO Capital Markets from a "market perform" rating to a "buy" rating.
Ratings data for MRNA provided by MarketBeat
Moderna (NASDAQ:MRNA) had its price target raised by analysts at Piper Sandler from $63.00 to $69.00. They now have an "overweight" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (MRNA) had its price target raised by Bank of America Corporation from $32.00 to $34.00. They now have an "underperform" rating on the stock.
Ratings data for MRNA provided by MarketBeat
Moderna (MRNA) had its "overweight" rating reaffirmed by Piper Sandler.
Ratings data for MRNA provided by MarketBeat
Neueste Beiträge
Wolfe_Research in Ashland Inc. diskutieren